Journal: Cell Cycle

Article Title: Identification of progression markers for prostate cancer

doi: 10.1080/15384101.2025.2563930

Figure Lengend Snippet: Results from the univariate survival analysis in PRAD. (a) Survival analysis log-rank test results. Bar plot shows the −log10 p-values obtained for molecular and clinical features, based on univariate analysis including the full PRAD cohort. Only features found to be significantly associated with at least one clinical endpoint are shown. Dashed line indicates the threshold for significant features. (b) Kaplan-Meier curves for the top four predictive molecular features for progression-free interval (PFI) based on univariate analysis including the full PRAD cohort. (c) PC-3 U cells were synchronized by double thymidine block and treated with or without APPL1 and APPL2 siRNA. Cells were released into fresh growth medium and cell lysates were prepared at different times for immunoblot analysis. (d) PC-3 U cells were transfected with or without APPL1 and APPL2 siRNA, incubated with nocodazole for 12 h, and then immunoblot analysis was performed.

Article Snippet: Antibodies against the following proteins were used for immunoblotting: APPL1 (Cell Signaling Technology Cat# 3858), APPL2 (Santa Cruz Biotechnology Cat# sc-67403, RRID:AB_2056383), VPS4A (Abcam Cat #ab229806), VPS4B (Abcam Cat #ab137027), β-tubulin (Cell Signaling Technology Cat# 2146, RRID:AB_2210545), and Horseradish peroxidase – coupled secondary antibodies were purchased from Dako and Protein-G Sepharose and ECL immunoblotting detection reagents from GE Healthcare.

Techniques: Blocking Assay, Western Blot, Transfection, Incubation